Intercytex
From Wikipedia, the free encyclopedia
| Intercytex | |
|---|---|
| Type | Public (LSE: ICX) |
| Founded | 2000 |
| Headquarters |  Cambridge, UK |
| Key people | Nick Higgins (CEO) Richard Moulson (CFO) Paul Kemp (CSO) |
| Industry | Biotechnology |
| Products | 4 in clinical development |
| Employees | 80[1] |
| Website | www.intercytex.com |
Intercytex is a biopharmaceutical company based in Cambridge, UK.
It was founded in 2000 and is the leading developer of regenerative medicine products to restore skin and hair[2].
Contents |
[edit] Products
Currently the company doesn't have a marketed product, though its pipeline includes one drug in phase III clinical development, two in phase II clinical development, and one in phase I clinical development[3].
| Drug | Phase | Action |
|---|---|---|
| ICX-PRO | Phase III clinical trial | Active repair in chronic wounds |
| VAVELTA | Phase II clinical trial | Facial rejuvenation and skin damage repair |
| ICX-TRC | Phase II clinical trial | Hair regeneration |
| ICX-SKN | Phase I clinical trial | Skin graft replacement |
[edit] Latest Research Developments
In June 2008, Intercytex announced positive results of their Phase II trial for a form of cloning based Hair multiplication technique called follicular cell implantation[4]. The treatment is being hailed as a major advance in hair restoration and is backed by a £1.9 million government grant. The treatment is predicted to be availale to patients within 5 years.
[edit] References
[edit] External links
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
